An Open-label Study for Participants Who Are Non-responders at the End of

See also
Status	Clinical Trial	Phase
Completed	`NCT04583735` - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Phase 4
Active, not recruiting	`NCT05002998` - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Phase 4
Withdrawn	`NCT02422368` - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease	Phase 2/Phase 3
Completed	`NCT03298867` - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study	Phase 3
Recruiting	`NCT05987423` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05517447` - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease	Phase 3
Terminated	`NCT04737330` - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT05517421` - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease	Phase 3
Recruiting	`NCT04311606` - Anti-VEGF Therapy for Acute Thyroid Eye Disease	Phase 2
Recruiting	`NCT06106828` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)	Phase 3
Recruiting	`NCT06021054` - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)	Phase 3
Not yet recruiting	`NCT06413043` - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy	N/A
Not yet recruiting	`NCT06401044` - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06384547` - A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT06367517` - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation	`NCT05241626` - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting	`NCT05776121` - Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Phase 1
Recruiting	`NCT04359979` - Tamsulosin for Thyroid Lid Retraction	N/A

NCT number	NCT06179875
Study type	Interventional
Source	Viridian Therapeutics, Inc.
Contact
Status	Recruiting
Phase	Phase 3
Start date	February 1, 2023
Completion date	March 2026

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms